- Home
- FUSB vs TIL Comparison
FUSB vs TIL Comparison
Compare FUSB & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FUSB | TIL |
|---|---|---|
| Founded | 1952 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 74.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FUSB | TIL |
|---|---|---|
| Price | $13.53 | $10.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $100.67 |
| AVG Volume (30 Days) | 9.3K | ★ 51.9K |
| Earning Date | 01-26-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $36,068,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.30 | $10.69 |
| 52 Week High | $14.79 | $42.79 |
Technical Indicators
Market Signals| Indicator | FUSB | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 49.66 | 37.22 |
| Support Level | $12.90 | $11.00 |
| Resistance Level | $13.71 | $11.60 |
| Average True Range (ATR) | 0.30 | 0.56 |
| MACD | -0.05 | 0.21 |
| Stochastic Oscillator | 41.47 | 10.98 |
Price Performance
Historical ComparisonAbout FUSB First US Bancshares Inc.
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.